In the last decade the endogenous estradiol metabolite, 2-methoxyestradiol (2ME), has
gained more and more interest due to its marked anticancerogenic properties and possible
cardiovascular benefits, as shown in numerous animal and experimental investigations.
Some promising results in terms of the usage of 2ME as a therapeutic agent were obtained
by various clinical studies in patients with breast cancer and prostate cancer. However, one
main problem appears to be the bioavailability of 2ME, therefore new formulations are now …